Press Release
Daré Bioscience to Participate in Three November Conferences
Event: Collaborating for Novel Solutions (CNS) Summit 2023
Format: Session Moderation by
Session:
Date / Time:
Location:
Details: The session will explore the high-return opportunities to advance women’s health R&D through collaboration, and how doing so is the key to accessing and offering healthcare solutions to the people who control 80% of the healthcare purchasing decisions. The speakers will be:
Imran Nasrullah ,MS, JD , Vice President & Head, Collaborate to Cure Hub US,Business Development & Licensing ,Bayer Pharmaceuticals Andrew Khair , Director, Strategy, Business Development, New Product Planning, Ferring Pharmaceuticals
Event: Stifel 2023 Healthcare Conference
Format: Company Presentation by
Date / Time:
Location: New
Details: A live webcast of Ms. Johnson’s presentation will be available at https://wsw.com/webcast/stifel83/dare/2064568 and under “Presentations, Events & Webcasts" in the Investors section of the company's website at https://ir.darebioscience.com. The webcast will be archived in the same section of the company’s website and available for replay until
Event:
Format: Abstract Presentation by
Session: Innovation & Sexual Medicine (non-CME)
Date / Time: Saturday, November 18, 2023;
Location:
Details: Dr. Goldstein will present an abstract titled “Preliminary Efficacy of Sildenafil Cream, 3.6% in an Exploratory, Randomized, Placebo-Controlled, Phase 2b Trial for the Treatment of Female Sexual Arousal Disorder.”
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.
Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose
Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com),
Contacts:
Media and Investors on behalf of Daré Bioscience, Inc:
Camilla White / Simona Kormanikova
DareBioscience@dentonsglobaladvisors.com / 1.212.466.6450
Source: Daré Bioscience, Inc.
Source: Daré Bioscience, Inc.